J&K Bank Q1 results: Net profit up 17% YoY to Rs 485 crore, NII grows 7%
Net interest income (NII) rose 7% to Rs 1,465 crore from Rs 1,369 crore, while other income jumped 29% to Rs 250 crore. Operating profit also saw a 13% rise, coming in at Rs 673 crore.
Gross NPA improved to 3.50% YoY (though slightly up sequentially from 3.37%), while Net NPA remained stable at 0.82%. The NPA Coverage Ratio remained strong at above 90%.
The bank's deposits grew 12% YoY to Rs 1.49 lakh crore, and net advances rose 6% to Rs 1.01 lakh crore. CASA ratio stood at 45.71%, while Return on Assets (RoA) improved to 1.17%.
Capital Adequacy Ratio (CAR) was reported at 15.98%, giving the bank a strong buffer for future growth. MD & CEO Amitava Chatterjee stated the bank is witnessing improving ground conditions and remains focused on expanding Rest of India operations and digital capabilities.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 minutes ago
- Business Upturn
Kotak Mahindra Bank Q1 results: Net profit down 47% YoY to Rs 3,282 crore, GNPA at 1.48% vs 1.39% QoQ
Kotak Mahindra Bank reported a 47.5% year-on-year (YoY) decline in net profit for the quarter ended June 30, 2025, with Q1 FY26 profit standing at Rs 3,281.68 crore compared to Rs 6,249.82 crore in Q1 FY25. The sharp fall is primarily due to the absence of exceptional gains booked in the same quarter last year. Net Interest Income (NII) grew 6% YoY to Rs 7,259 crore from Rs 6,843 crore, reflecting steady growth in lending and core banking operations. Total income rose to Rs 16,916 crore from Rs 15,675 crore YoY. Operating profit (before provisions) rose to Rs 5,563.69 crore from Rs 5,254.11 crore in the previous year. Provisions and contingencies, however, jumped to Rs 1,207.76 crore from Rs 578.48 crore YoY, impacting the bank's profitability. Asset quality weakened slightly: Gross NPA: Rs 6,637.70 crore (1.48%) vs Rs 5,477.15 crore (1.39%) QoQ Net NPA: Rs 1,530.93 crore (0.34%) vs Rs 1,376.33 crore (0.35%) QoQ Despite steady growth in core income, the YoY profit decline was driven by the high base effect of last year's Rs 3,519.90 crore exceptional gain. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Insider
an hour ago
- Business Insider
How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life
Biopharma giant Johnson & Johnson's (JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving the market a clear signal that it's reigniting growth with practically flawless numbers—a potential turning point for the second half of the year. The upwardly revised guidance and expectations for strong margin expansion, despite lingering litigation concerns, have brought fresh optimism to the stock and appeased shareholders clamoring for added value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. While the stock isn't as discounted as it was earlier this year, valuations still look reasonable. Given JNJ's strong compounding potential and this renewed bullish momentum, I see it as a Buy. How J&J's Strong Quarter Sets the Stage for Growth Johnson & Johnson stock has been rangebound for years, weighed down by a mix of factors, including a massive wave of lawsuits claiming its talc-based baby powder caused cancer due to asbestos contamination, as well as expiring drug patents, such as its blockbuster Stelara losing exclusivity. Last but not least is sluggish growth and an eroded safe-haven reputation, since legacy consumer brands like Tylenol, Listerine, and Band-Aid have low growth and face margin pressure from cheap competition. According to TipRanks data, JNJ has underperformed the S&P quite considerably since 2024. Johnson & Johnson's latest Q2 earnings may mark a true inflection point toward more consistent alpha generation. The company delivered exactly what it needed— beating both earnings and revenue expectations —while issuing a notable upward revision to guidance: an additional $2 billion in forecasted sales and $0.25 more in projected EPS. For a pharma giant like J&J, that's a clear signal of renewed momentum following a prolonged period of litigation-related overhang. Management also reaffirmed its full-year outlook for a 300-basis-point improvement in operating margin, raising it from approximately 25.4% to 28.4%. Notably, the quarter wasn't just about numbers. J&J reported compelling 5-year trial results for its multiple myeloma immunotherapy—an encouraging sign in the fight against a challenging cancer. The company also set an ambitious goal: to become the global leader in oncology by 2030, with a target of over $50 billion in cancer drug sales. With a potential $5 billion peak opportunity in bladder cancer and a strong pipeline aimed at offsetting losses from aging blockbusters, J&J is signaling that real innovation is back at the forefront. Breaking Free from the Margin Squeeze While markets often reward margin expansion, Johnson & Johnson looks especially well-positioned to benefit going forward. In addition to raising full-year earnings guidance, the company also delivered positive updates on cost pressures— halving its expected tariff impact from $400 million to $200 million and projecting a $1.1 billion tailwind from favorable currency shifts as the U.S. dollar weakens. The reduced tariff burden is primarily attributed to the MedTech division, which is more exposed to global supply chains and international manufacturing than the pharmaceutical segment. That's a clear tailwind for margins and future profitability. It's also important to note how strategic portfolio decisions have helped set the stage for this improvement. The 2023 spin-off of Kenvue—essentially the entire Consumer Health business—removed a lower-margin segment from the mix, sharpening J&J's focus on higher-margin areas. This move highlights the company's commitment not only to defending margins but also to actively growing them. In today's market, stability alone isn't enough—investors are looking for real margin expansion, and Johnson & Johnson seems intent on delivering. Analysts have responded by raising their EPS estimates for 2025 and 2026 by about 2% compared to before Q2 earnings. They now expect full-year EPS in 2025 to hit $10.86 —an 8.7% increase from last year—and to reach $11.34 in 2026, representing an annual growth rate of 4.4%. Reasonable Valuation with Growth on the Horizon Johnson & Johnson is a vast, stable, and diversified company, so its valuation tends to reflect relative stability rather than wild growth. Looking at its forward earnings multiple, currently around 15.5x, it's basically in line with the five-year average. This is well above the lows seen earlier this year, when it traded as low as 11x forward earnings in January. To me, this suggests the valuation isn't necessarily cheap, but it's reasonable. Comparing J&J's current earnings multiples over the last twelve months to its main peers, the 17.5x P/E ratio sits close to the sector average. Except for Merck & Co. (MRK), J&J is actually one of the more discounted names in the group. Finally, with a dividend yield of almost 3%, the stock no longer appears exuberant, and the yield isn't particularly compelling—especially when compared to the 10-year U.S. Treasury yield. However, J&J's payout ratio is typically safe, at around 50% of earnings, which helps build shareholder trust. Additionally, the market is now anticipating a more positive growth trajectory following the recent upward revisions to guidance, both last quarter and earlier this year. Is JNJ Stock a Buy, Hold, or Sell? Wall Street sentiment on Johnson & Johnson remains mixed, with more caution than conviction among analysts. Of the 19 analysts who have issued ratings over the past three months, nine are bullish, while the remaining ten are neutral. The average price target stands at $176.35, suggesting a modest upside of approximately 4.3% from the current share price. Johnson & Johnson Positioned for Consistent Alpha Generation Johnson & Johnson has, in my view, successfully restored market confidence in both its innovation pipeline and cost discipline—key pillars that could drive renewed growth and support reliable shareholder returns for decades to come. For long-term investors, initiating a position now is essentially a bet on a proven dividend combined with steady capital appreciation—an attractive formula that has historically outperformed the broader market. While the stock appears fairly valued at current levels, it offers compelling potential for compounding returns and consistent alpha generation in the years ahead.
Business Upturn
16 hours ago
- Business Upturn
J&K Bank Q1 results: Net profit up 17% YoY to Rs 485 crore, NII grows 7%
Jammu & Kashmir Bank reported its #Q1Results with a strong performance in profitability and stable asset quality. The bank posted a net profit of Rs 484.84 crore for the April–June quarter of FY26, marking a 16.7% year-on-year increase from Rs 415.49 crore in Q1 FY25. The improvement came despite a one-time impairment provision of Rs 87 crore related to its investment in J&K Grameen Bank post-amalgamation. Without this impact, YoY profit growth would have exceeded 30%, the bank noted. Net interest income (NII) rose 7% to Rs 1,465 crore from Rs 1,369 crore, while other income jumped 29% to Rs 250 crore. Operating profit also saw a 13% rise, coming in at Rs 673 crore. Gross NPA improved to 3.50% YoY (though slightly up sequentially from 3.37%), while Net NPA remained stable at 0.82%. The NPA Coverage Ratio remained strong at above 90%. The bank's deposits grew 12% YoY to Rs 1.49 lakh crore, and net advances rose 6% to Rs 1.01 lakh crore. CASA ratio stood at 45.71%, while Return on Assets (RoA) improved to 1.17%. Capital Adequacy Ratio (CAR) was reported at 15.98%, giving the bank a strong buffer for future growth. MD & CEO Amitava Chatterjee stated the bank is witnessing improving ground conditions and remains focused on expanding Rest of India operations and digital capabilities. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
